Dyslipidemia

>

Latest News

US FDA logo in black over a white background. | Credit: US Food and Drug Administration
FDA Grants Priority Review for Olezarsen in Familial Chylomicronemia Syndrome

June 25th 2024

The FDA accepted the NDA for olezarsen, an RNA-targeted medicine, in familial chylomicronemia syndrome for priority review, with a PDUFA date set for December 19, 2024.

Clinical Quiz: Pharmacotherapy Recommendations from ESC/EAS 2019 Dyslipidemia Guidelines
Clinical Quiz: Pharmacotherapy Recommendations from ESC/EAS 2019 Dyslipidemia Guidelines

June 25th 2024

Machine Learning Boosts Accuracy in Identifying Familial Hypercholesterolemia
Machine Learning Boosts Accuracy in Identifying Familial Hypercholesterolemia

June 25th 2024

Pushkal Garg, MD | Image Credit: Alnylam Pharmaceuticals
Vutrisiran Reduces Mortality, CV Events in ATTR-CM in Phase 3 Trial

June 24th 2024

Kristina Krasieva, MD | Credit: LinkedIn
Study Reveals Gender Disparities in Long-Term Lipid Management After ACS for FH Patients

June 21st 2024

Video Series
Video Interviews
Podcasts

More News

© 2024 MJH Life Sciences

All rights reserved.